^
    Back
    Association details:
    Biomarker:miR-142 overexpression
    Cancer:Ovarian Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Ovarian Res
    Title:

    Bevacizumab confers significant improvements in survival for ovarian cancer patients with low miR-25 expression and high miR-142 expression

    Published date:
    11/22/2021
    Excerpt:
    …patients with low miR-25 expression benefited significantly from bevacizumab treatment in terms of PFS...patients with high miR-142 expression benefited significantly from bevacizumab treatment in terms of PFS and OS. In conclusion, miR-25 expression correlates with a better PFS and OS in ovarian cancer. Patients with low miR-25 expression and high miR-142 expression could benefit from bevacizumab treatment significantly.
    DOI:
    10.1186/s13048-021-00915-9